Published by Josh White on 1st July 2024
(Sharecast News) - AstraZeneca announced on Monday that 'Imfinzi', or durvalumab, and 'Lynparza', or olaparib, have received a recommendation for approval in the European Union (EU) as treatments for primary advanced or recurrent endometrial cancer in patients with specific genetic profiles.